{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:31:40Z","timestamp":1784561500420,"version":"3.55.0"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","award":["EUPAS44035"],"award-info":[{"award-number":["EUPAS44035"]}],"id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To monitor the safety and utilisation of AZD1222 under real-world use in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A non-interventional post-authorisation active surveillance study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Vaccination sites in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 17\u2009945 participants were eligible and provided consent to participate in the study between 1 March 2021 and 6 April 2023. Participants were followed up at weeks 1, 4 and 14 and at months 6, 9, 12 and 18 after the first dose of AZD1222 vaccination and prompted to complete electronic data capture forms. A total of 11\u2009219 participants submitted a Follow-Up 1 form and 5189 participants submitted a Follow-Up 7 form (at 18 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The safety of AZD1222, including the identification, assessment and quantification of serious adverse events (SAEs) and adverse events of special interest (AESI), was examined. The utilisation of AZD1222 was described and characterised, including populations with missing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority of participants were women (n=10\u2009845; 60.4%) and the median age (IQR) was 50 (43, 62) years. Most participants were from white ethnic groups (n=13\u2009112; 73.1%). Headache and fatigue had the highest reported incidence rate (421.28 cases per 1000 person years and 386.00 cases per 1000 person years, respectively). The most frequently reported AESI was anosmia (6.25 cases per 1000 person years). An increased Observed versus Expected (O:E) ratio was seen for anaphylaxis (O:E 7.38 (95% CI 2.80 to 11.95); based on 10 observed cases (expected cases: 1.36)) and anosmia and\/or ageusia (O:E 39.23 (95% CI 29.13 to 49.32), based on 58 observed cases (expected cases: 1.48)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The most frequent vaccinee-reported adverse events (AEs) were headache and fatigue. An increased O:E ratio was seen for the AEs of anaphylaxis and anosmia and\/or ageusia. No safety signals were identified throughout the course of this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>This study is registered with the HMA-EMA Catalogue of RWD studies (EUPAS44035).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093366","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:06:15Z","timestamp":1746173175000},"page":"e093366","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-2429","authenticated-orcid":false,"given":"Alison","family":"Evans","sequence":"first","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-6323","authenticated-orcid":false,"given":"Debabrata","family":"Roy","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-8378","authenticated-orcid":false,"given":"Miranda","family":"Davies","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dhanda","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Morris","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Aurelius","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-1149","authenticated-orcid":false,"given":"Samantha","family":"Lane","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5307-1297","authenticated-orcid":false,"given":"Catherine","family":"Fry","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Shakir","sequence":"additional","affiliation":[{"name":"Drug Safety Research Unit, Southampton, UK"},{"name":"University of Portsmouth, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025121601470438000_15.5.e093366.1","unstructured":"European Medicines Agency . COVID-19 vaccines: development, evaluation, approval and monitoring. 2021. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-development-evaluation-approval-monitoring"},{"key":"2025121601470438000_15.5.e093366.2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"key":"2025121601470438000_15.5.e093366.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111507"},{"key":"2025121601470438000_15.5.e093366.4","unstructured":"Available: https:\/\/www.gov.uk\/government\/news\/oxford-universityastrazeneca-vaccine-authorised-by-uk-medicines-regulator"},{"key":"2025121601470438000_15.5.e093366.5","unstructured":"Available: https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020\/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020"},{"key":"2025121601470438000_15.5.e093366.6","unstructured":"Available: https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-phase-2-of-the-coronavirus-covid-19-vaccination-programme-advice-from-the-jcvi\/jcvi-final-statement-on-phase-2-of-the-covid-19-vaccination-programme-13-april-2021"},{"key":"2025121601470438000_15.5.e093366.7","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use . Post-approval safety data management: definitions and standards for expedited reporting e2d current step 4 version. 2003."},{"key":"2025121601470438000_15.5.e093366.8","doi-asserted-by":"crossref","unstructured":"Machin D , Campbell MJ , Tan SB , et al . Sample size tables for clinical studies. 3rd edn. Wiley-Blackwell, John Wiley & Sons Ltd, 2009.","DOI":"10.1002\/9781444300710"},{"key":"2025121601470438000_15.5.e093366.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"2025121601470438000_15.5.e093366.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025121601470438000_15.5.e093366.11","unstructured":"Available: https:\/\/www.gov.uk\/government\/news\/statement-from-the-uk-chief-medical-officers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines"},{"key":"2025121601470438000_15.5.e093366.12","unstructured":"Available: https:\/\/www.gov.uk\/government\/publications\/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022\/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022"},{"key":"2025121601470438000_15.5.e093366.13","unstructured":"Available: https:\/\/www.gov.uk\/government\/news\/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40#:~:text=As%20COVID%2D19%20rates%20continue,delays%20in%20having%20the%20vaccine"},{"key":"2025121601470438000_15.5.e093366.14","unstructured":"European medicines agency . Summary of product characteristics. covid-19 vaccine astrazeneca. 2021."},{"key":"2025121601470438000_15.5.e093366.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.073221"},{"key":"2025121601470438000_15.5.e093366.16","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.97.12.571"},{"key":"2025121601470438000_15.5.e093366.17","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1016\/j.vaccine.2022.08.007","article-title":"Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations","volume":"40","author":"Laffan","year":"2022","journal-title":"Vaccine (Auckl)"},{"key":"2025121601470438000_15.5.e093366.18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine (Auckl)"},{"key":"2025121601470438000_15.5.e093366.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"2025121601470438000_15.5.e093366.20","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28771","article-title":"Oral side effects of COVID-19 vaccines in 32 European countries: Analysis of EudraVigilance reports","volume":"95","author":"Riad","year":"2023","journal-title":"J Med Virol"},{"key":"2025121601470438000_15.5.e093366.21","unstructured":"Based on ONS mid-2021 data, Available: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-19-vaccinations\/; https:\/\/research.senedd.wales\/research-articles\/covid-19-vaccination-data\/; https:\/\/covid-19.hscni.net\/ni-covid-19-vaccinations-dashboard\/; https:\/\/www.opendata.nhs.scot\/dataset\/covid-19-vaccination-in-scotland"},{"key":"2025121601470438000_15.5.e093366.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"},{"key":"2025121601470438000_15.5.e093366.23","unstructured":"Based on UK census. 2011. Available: https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/covid-19-vaccinations\/; https:\/\/research.senedd.wales\/research-articles\/covid-19-vaccination-data\/; https:\/\/covid-19.hscni.net\/ni-covid-19-vaccinations-dashboard\/; https:\/\/publichealthscotland.scot\/media\/8946\/21-09-01-covid19-publication_report.pdf"},{"key":"2025121601470438000_15.5.e093366.24","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp13X668456"},{"key":"2025121601470438000_15.5.e093366.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n513","article-title":"Covid-19 vaccine hesitancy among ethnic minority groups","volume":"372","author":"Razai","year":"2021","journal-title":"BMJ"},{"key":"2025121601470438000_15.5.e093366.26","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(21)00404-7","article-title":"Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK","volume":"21","author":"Kadambari","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025121601470438000_15.5.e093366.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:47:18Z","timestamp":1765878438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2024-093366"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093366","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}